PD-013 - RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
Saved in:
| Title: | PD-013 - RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). |
|---|---|
| Authors: | Sunakawa, Y.1 (AUTHOR), Nakamura, M.2,3 (AUTHOR), Ishizaki, M.4 (AUTHOR), Kataoka, M.5 (AUTHOR), Satake, H.6 (AUTHOR), Kitazono, M.7 (AUTHOR), Yanagisawa, H.8 (AUTHOR), Kawamoto, Y.9 (AUTHOR), Kuramochi, H.10 (AUTHOR), Ohori, H.11 (AUTHOR), Takahashi, K.12 (AUTHOR), Maeda, F.12 (AUTHOR), Komeno, C.12 (AUTHOR), Takeuchi, M.13 (AUTHOR), Fujii, M.14 (AUTHOR), Yoshino, T.15 (AUTHOR), Ichikawa, W.16 (AUTHOR), Tsuji, A.17 (AUTHOR) |
| Source: | Annals of Oncology. 2019 Supplement, Vol. 30, piv114-iv114. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz156.012 |
